Sustaining GAVI-supported vaccine introductions in resource-poor countries.

Authors:
Address: Department of Immunization, Vaccines and Biologicals, World Health Organization, 20 Av. Appia, 1211 Geneva, Switzerland. ZUBERP@WHO.INT
Journal:

Publication:

abstract

Since 2000, GAVI provided essential support for an unprecedented increase in the use of hepatitis B (HepB) and Haemophilus influenzae (Hib) containing vaccines in resource poor countries. This increase was supported with significant funding from international donors, intended to be time-limited. To assess the sustainability of this important expansion of the global access to vaccines, we reviewed supply chains, financial resources for procurement and decision-making in countries that introduced hepatitis B or Hib vaccines with GAVI support. During the period studied, the types of vaccine products supplied fluctuated rapidly in relationship with the number of suppliers and availability of more combination products. The price of the cheaper vaccines decreased while that of pentavalent DTwP-HepB-Hib remained stable. In average, vaccine introduction was associated with an increase of national programs budget, with new vaccines representing more than half of that increase, while the part of GAVI contributions to the budget went from 25% to 46%. Less than 20% of the vaccine introductions were decided by a national advisory body. Strengthening supply chains, adjusting funding schemes and increasing national ownership will be key to the sustained use of hepatitis B and Hib vaccines and the eventual addition of other important vaccines where they are the most needed.

Related Articles
Review Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type B vaccine experience.
Philos Trans R Soc Lond B Biol...
Review Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type B vaccine experience.
Hajjeh R. Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12; 366(1579):2827-32.
Review Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
Vaccine. 2008
Review Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
Lydon P, Levine R, Makinen M, Brenzel L, Mitchell V, Milstien JB, Kamara L, Landry S. Vaccine. 2008 Dec 2; 26(51):6706-16.
Global use of Haemophilus influenzae type b conjugate vaccine.
Vaccine. 2010
Global use of Haemophilus influenzae type b conjugate vaccine.
Ojo LR, O'Loughlin RE, Cohen AL, Loo JD, Edmond KM, Shetty SS, Bear AP, Privor-Dumm L, Griffiths UK, Hajjeh R. Vaccine. 2010 Oct 8; 28(43):7117-22. Epub 2010 Aug 4.
Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Vaccine. 2005
Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM, Gleizes O, Covilard JP. Vaccine. 2005 Aug 31; 23(37):4610-8.
Progress toward introduction of Haemophilus influenzae type b vaccine in low-income countries--worldwide, 2004-2007.
MMWR Morb Mortal Wkly Rep. 2008
Progress toward introduction of Haemophilus influenzae type b vaccine in low-income countries--worldwide, 2004-2007.
Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2008 Feb 15; 57(6):148-51.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.